Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2015 - 2026)

Fulgent Genetics has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$29.5 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 55.77% year-over-year to -$29.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$84.4 million (down 65.38% YoY) and the FY2025 annual result came in at -$60.5 million, down 41.69% from the prior year.
• Net Income towards Common Stockholders eased to -$29.5 million in Q2 2026 per FLGT's latest filing, from -$24.8 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $153.6 million in Q1 2022 and troughed at -$128.1 million in Q4 2023.
• A 5-year average of -$10.2 million and a median of -$13.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 1075.95% in 2023, then soared 95.41% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$24.1 million in 2022, then tumbled by 432.27% to -$128.1 million in 2023, then jumped by 95.41% to -$5.9 million in 2024, then sank by 297.72% to -$23.4 million in 2025, then fell by 26.1% to -$29.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$29.5 million, -$24.8 million, and -$23.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.